Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| ERID-EK/158 | Other Identifier | Ethics Committee of the Institute of Oncology Ljubljana |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to introduce appropriate assessment instruments and to define patients with gliomas according to cognitive functioning and quality of life. The study will evaluate cognitive functioning as a prognostic factor for survival in patients with glial tumors and will support optimization of treatment strategies to improve patients' quality of life.
This prospective cohort study will assess cognitive functioning and quality of life in patients with glial tumors. The objective is to determine the prognostic value of cognitive functioning on survival, establish appropriate assessment instruments, and contribute to treatment adaptation with the goal of improving quality of life in these patients.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Glioma Patients | Other | Patients with glial tumors assessed for quality of life and cognitive functioning as prognostic factors. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cognitive Functioning and Quality of Life Assessment | Other | Assessment of cognitive functioning and quality of life in patients with glial tumors to evaluate their prognostic value and impact on survival outcomes. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Quality of Life Score (EORTC QLQ-C30 and QLQ-BN20) | Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer questionnaires EORTC QLQ-C30 and the brain cancer module EORTC QLQ-BN20. Scores range from 0 to 100 points. The outcome will be reported as mean change in questionnaire score (points) from baseline to each follow-up assessment. | Baseline (before treatment); 6 weeks; 3 months; 6 months; 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Cognitive Function Test Performance (Neuropsychological Test Battery) | Cognitive functioning will be assessed using a neuropsychological test battery evaluating multiple cognitive domains (e.g., language, memory, executive functioning). The outcome will be reported as mean change in test scores from baseline to each follow-up assessment. | Baseline (before treatment); 6 weeks; 3 months; 6 months; 12 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institute of Oncology Ljubljana | Ljubljana | 1000 | Slovenia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005910 | Glioma |
| ID | Term |
|---|---|
| D018302 | Neoplasms, Neuroepithelial |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D009369 | Neoplasms |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009380 | Neoplasms, Nerve Tissue |